← Back to Patent Explorer
US4059686A Expired / Lapsed US ⏱️ 0.0 years remaining

Pharmaceutical preparation for oral cavity administration

Assignee: Nippon Kayaku Co Ltd
•
Filing: 1975-09-22
•
Granted: 1977-11-22
•
Expires: 1995-09-22
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A pharmaceutical preparation of oral cavity administration, characterized by being a mixture of a pharmacologically active agent, a pharmaceutical carrier, and sodium polyacrylate, in conventional dosage form. It has advantages in that it adheres strongly to local site and dissolves gradually over a prolonged period of time while releasing appropriate amounts of the active agent.

Inventors

  • 👤 Wataru Tanaka
  • 👤 Eiichiro Akito
  • 👤 Koichi Yoshida
  • 👤 Takashi Terada
  • 👤 Hiroshi Ninomiya

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 06:36
CPC Classifications
A; A61; A61K; A61K47/00; A61K47/30; A61K47/32; A61K9/00; A61K9/0012; A61K9/0053; A61K9/006; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2027

Claims Analysis

Total Claims: 9
Claim 1
Independent Claim 46 words
A pharmaceutical preparation for oral cavity administration comprising 10 to 60% by weight of sodium polyacrylate, 90 to 10% by weight of a pharmaceutical carrier selected from the group consisting of an excipient and ointment, and 50 to 0.05% by weight of a pharmacologically active agent.
Claim 2
Dependent Claim 46 words
A pharmaceutical preparation for oral cavity administration comprising 10 to 60% by weight of sodium polyacrylate, 90 to 10% by weight of a pharmaceutical carrier selected from the group consisting of an excipient and ointment, and 50 to 0.05% by weight of a pharmacologically active agent.
Claim 3
Dependent Claim 24 words
A pharmaceutical preparation for oral cavity administration according to claim 1, wherein the sodium polyacrylate has an average molecular weight of 185,000 to 8,500,000.
Claim 4
Dependent Claim 32 words
A pharmaceutical preparation for oral cavity administration according to claim 1, wherein the excipient is microcrystalline cellulose, mannitol, crystalline lactose, spray-dried lactose, sorbitol, anhydrous calcium phosphate, amylose, powdered lactose, or powdered sucrose.
Claim 5
Dependent Claim 41 words
A pharmaceutical preparation for oral cavity administration according to claim 1, wherein the ointment base is white petrolatum, polyethylene glycol, a compatible mixture of peanut oil or purified sesame oil with beeswax, or a compatible mixture of polyethylene and liquid paraffin.
Claim 6
Dependent Claim 49 words
A pharmaceutical preparation for oral cavity administration according to claim 1, wherein the pharmacologically active agent is selected from the group consisting of a steroid hormone, an antiinflammatory steroid, an antiinflammatory enzyme, callicrein, a peptide, a nitrate ester, isoproterenol, methacholine, an antibiotic, a lysozyme, dextrinase, and a local anesthetic.
Claim 7
Dependent Claim 31 words
A pharmaceutical preparation for oral cavity administration according to claim 1, wherein the said pharmaceutical is selected from the group consisting of a buccal tablet, a sublingual tablet, and an ointment.
Claim 8
Dependent Claim 59 words
A pharmaceutical preparation for oral cavity administration according to claim 1, wherein the pharmaceutical preparation comprising 10 to 60% by weight of sodium polyacrylate, 80 to 10% by weight of an excipient and 50 to 0.05% by weight of a pharmacologically active agent is a tablet selected from the group consisting of a buccal tablet and a sublingual tablet.
Claim 9
Dependent Claim 47 words
A pharmaceutical preparation for oral cavity administration according to claim 1, wherein the pharmaceutical preparation comprising 10 to 50% by weight of sodium polyacrylate, 90 to 40% by weight of an ointment base, and 10 to 0.05% by weight of a pharmacologically active agent is an ointment.

References Cited (Backward Citations)

US3029188A Cited
US2987445A Cited
US3147187A Cited
GB1233055A Cited
DE2017409A1 Cited
US3911099A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1980-11-21 1981-05-23 1981-11-22 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1984-11-21 1985-05-23 1985-11-22 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1988-11-21 1989-05-23 1989-11-22 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag